ArticleInternational journal of general medicine2026
A Multi-Center Study: Developing a Nomogram for Predicting Genetic Results of Trio-Based Whole-Exome Sequencing (Trio-WES) in Diagnosing Children with Syndromic Neurodevelopmental Disorders (s-NDDs).
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The diagnostic efficacy of empirical trio-based whole-exome sequencing (trio-WES) for unexplained syndromic neurodevelopmental disorders (NDDs) remains unsatisfactory. This study aimed to explore the diagnostic value of phenotypic indicators and establish a nomogram for predicting the genetic results of trio-WES for diagnosing patients with unexplained s-NDDs. Methods: We retrospectively collected phenotypic and genotypic data from 265 children with s-NDDs who received trio-WES at Sun Yat-sen Memorial Hospital (training cohort), 38 and 97s-NDDs patients with trio-WES test at Shenshan Medical Center (validation cohort-1) and Weierkang Children's Rehabilitation Center (validation cohort-2), respectively. Logistic analysis was employed to identify the independent predictors of a positive trio-WES diagnosis in the training cohort for model establishment. The predictive performance and robustness of the model were assessed using receiver operating characteristic (ROC) and confusion matrix analyses, respectively. Results: The analysis revealed that the severity of neurodevelopmental delays, head circumference abnormality, and complexity of neurodevelopmental comorbidities were independent predictive indicators for distinguishing s-NDDs patients with positive trio-WES results. The nomogram combining the three predictors showed good predictive performance with an area under the ROC (AUC) in the training cohort of 0.827 (95% CI: 0.775-0.879), yielding a confusion matrix with sensitivity, specificity, accuracy, precision, and F1 score of 78.23%, 78.01%, 78.11%, 75.78%, and 0.77, respectively. The model also had an excellent prediction in the external validation cohorts (AUC: 0.953; 95% CI: 0.881-0.998, sensitivity: 88.89%; specificity: 80.00%; accuracy: 84.21%; precision: 80.00%; and F1 score: 0.84 in validation cohort-1 and AUC: 0.910; 95% CI: 0.843-0.978, sensitivity: 83.33%; specificity: 85.45%; accuracy: 84.54%; precision: 81.40%; and F1 score: 0.82 in validation cohort-2). Conclusion: The model can serve as a useful tool for assisting decision-making in applying trio-WES in the diagnostic strategy for s-NDDs, helping to implement personalized pre-diagnosis assessments for affected families.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.